Authors: Stebbing, J Benson, C Eisen, T Pyle, L Smalley, K Bridle, H Mak, I Sapunar, F Ahern, R Gore, ME

Citation: J. Stebbing et al., The treatment of advanced renal cell cancer with high-dose oral thalidomide, BR J CANC, 85(7), 2001, pp. 953-958

Authors: Vaughan, MM Moore, J Riches, PG Johnston, SRD A'Hern, RP Hill, ME Eisen, T Ayliffe, MJ Thomas, JM Gore, ME

Citation: Mm. Vaughan et al., GM-CSF with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): A phase I trial in melanoma, ANN ONCOL, 11(9), 2000, pp. 1183-1189

Authors: Smalley, K Eisen, T

Citation: K. Smalley et T. Eisen, The involvement of p38 mitogen-activated protein kinase in the alpha-melanocyte stimulating hormone (alpha-MSH)-induced melanogenic and anti-proliferative effects in B16 murine melanoma cells, FEBS LETTER, 476(3), 2000, pp. 198-202

Authors: Allen, MJ Vaughan, M Webb, A Johnston, S Savage, P Eisen, T Bate, S Moore, J Ahern, R Gore, ME

Citation: Mj. Allen et al., Protracted venous infusion 5-fluorouracil in combination with subcutaneousinterleukin-2 and alpha interferon in patients with metastatic renal cell cancer: a phase II study, BR J CANC, 83(8), 2000, pp. 980-985

Authors: Eisen, T Boshoff, C Mak, I Sapunar, F Vaughan, MM Pyle, L Johnston, SRD Ahern, R Smith, IE Gore, ME

Citation: T. Eisen et al., Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer, BR J CANC, 82(4), 2000, pp. 812-817